| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Hecogenin acetate targets multiple pathways and has diverse biological activities. It has anthelmintic properties, reducing mobile larvae of nematodes with an EC50 of 0.49 mg/ml. It has antinociceptive properties and may act on opioid receptors. The compound also has anti-inflammatory and analgesic properties. As a steroidal sapogenin, it is a key intermediate in the semi-synthesis of corticosteroids and other steroid-based pharmaceuticals.
|
|---|---|
| ln Vitro |
In vitro, hecogenin acetate has anthelmintic activity, reducing the percentage of mobile larvae in goat fecal cultures containing Haemonchus, Oesophagostomum, and Trichostrongylus nematodes (EC50 = 0.49 mg/ml). It has antinociceptive properties and may act on opioid receptors. The compound also has anti-inflammatory and analgesic properties. Its activity is typically evaluated using anthelmintic assays, pain models, and inflammation assays.
|
| ln Vivo |
In vivo, hecogenin acetate has antinociceptive activity, inhibiting descending pain. It has anti-inflammatory and analgesic properties. As a steroidal sapogenin, it is used as a key intermediate in the semi-synthesis of corticosteroids. However, specific in vivo efficacy data, including dosing regimens and animal models, are not extensively detailed in the available literature. Further studies are needed to fully characterize its in vivo pharmacological profile.
|
| Enzyme Assay |
Cell-free assays for hecogenin acetate involve evaluating its anthelmintic activity. Larval motility assays are performed using nematode larvae in culture. EC50 values (0.49 mg/ml) are determined from dose-response curves. Its ability to interact with opioid receptors can be assessed using receptor binding assays. The compound's chemical purity and identity are confirmed by HPLC, NMR, and mass spectrometry. It is typically dissolved in DMSO or appropriate solvents for assay preparation.
|
| Cell Assay |
In vitro cellular assays for hecogenin acetate typically involve treating cells with various concentrations of the compound to study its effects on inflammation and pain pathways. Anti-inflammatory activity is assessed by measuring cytokine production in activated immune cells. Antinociceptive activity is evaluated in neuronal cell models. However, specific assay protocols are not extensively documented in the available literature. The compound is typically dissolved in DMSO and diluted in cell culture medium.
|
| Animal Protocol |
In vivo animal studies for hecogenin acetate are conducted in models of pain, inflammation, and parasitic infection. The compound is administered via various routes including oral gavage or intraperitoneal injection. Pain responses are measured using behavioral assays. Inflammatory markers are measured in serum and tissues. Anthelmintic efficacy is assessed in animal models of nematode infection. However, specific dosing regimens and experimental protocols are not extensively documented in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of hecogenin acetate include a molecular weight of 472.67 g/mol, molecular formula C29H44O5, and purity ≥90%. It is a solid at room temperature and should be stored in a cool, dark place. As a steroidal sapogenin, it is expected to have moderate oral bioavailability. Detailed ADME parameters such as half-life, Cmax, and AUC are not extensively reported in the available literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of hecogenin acetate has not been extensively characterized in published literature. As a steroidal sapogenin, it is generally considered to have a manageable safety profile at research doses. Standard preclinical safety studies would include acute and sub-chronic toxicity assessments in rodent models. The compound is intended for research use only and not for therapeutic applications in humans.
|
| References |
|
| Additional Infomation |
Hycodin acetate is a triterpenoid compound.
Hecogenin acetate is a steroidal sapogenin with anthelmintic (EC50 = 0.49 mg/ml) and antinociceptive properties. It also has anti-inflammatory and analgesic properties. Its molecular formula is C29H44O5 with a molecular weight of 472.67 g/mol. Hecogenin acetate is a research tool and key intermediate for steroid synthesis. It is not for therapeutic use. |
| Molecular Formula |
C29H44O5
|
|---|---|
| Molecular Weight |
472.6567
|
| Exact Mass |
472.319
|
| CAS # |
915-35-5
|
| PubChem CID |
101906
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.15g/cm3
|
| Boiling Point |
557.5ºC at 760mmHg
|
| Melting Point |
246-248ºC (dec.)(lit.)
|
| Flash Point |
264.7ºC
|
| LogP |
5.543
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
34
|
| Complexity |
871
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(C(=O)C[C@H]5[C@H]4CC[C@@H]6[C@@]5(CC[C@@H](C6)OC(=O)C)C)C)C)OC1
|
| InChi Key |
CVKZWRTYHCDWTE-RSEFXUKDSA-N
|
| InChi Code |
InChI=1S/C29H44O5/c1-16-8-11-29(32-15-16)17(2)26-24(34-29)13-23-21-7-6-19-12-20(33-18(3)30)9-10-27(19,4)22(21)14-25(31)28(23,26)5/h16-17,19-24,26H,6-15H2,1-5H3/t16-,17+,19+,20+,21-,22+,23+,24+,26+,27+,28-,29-/m1/s1
|
| Chemical Name |
[(1R,2S,4S,5'R,6R,7S,8R,9S,12S,13S,16S,18S)-5',7,9,13-tetramethyl-10-oxospiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
THF : 57.5 mg/mL (~121.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1157 mL | 10.5784 mL | 21.1569 mL | |
| 5 mM | 0.4231 mL | 2.1157 mL | 4.2314 mL | |
| 10 mM | 0.2116 mL | 1.0578 mL | 2.1157 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
